Author

K.N. Chi

Observed names: K Chi, K. Chi, K.N.N. Chi

Institution: BC Cancer Agency

Observed institutions: BC Cancer Agency, University of British Columbia, Vancouver Prostate Centre

OpenAlex ID: A5110192270

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

2015 · K.N. Chi, T. Kheoh, et al. · Annals of Oncology · 167

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

2023 · O. Sartor, D.E. Castellano Gauna, et al. · Annals of Oncology · 70

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

2011 · C. Kollmannsberger, H. Hirte, et al. · Annals of Oncology · 40

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

2011 · K.N. Chi, E. Beardsley, et al. · Annals of Oncology · 37

LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

2023 · K.N.N. Chi, E. Castro, et al. · Annals of Oncology · 12

Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)

2021 · S. Chowdhury, A. Bjartell, et al. · European Urology · 4

618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN

2021 · J. Shen, S. Chowdhury, et al. · Annals of Oncology · 3

A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone

2016 · G. Attard, R. Montgomery, et al. · European Urology Supplements · 3

1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore

2024 · K. Fizazi, M.J. Morris, et al. · Annals of Oncology · 2

2535 Clinical outcomes in chemotherapy-naïve metastatic castrationresistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis

2015 · C.M. Aviles, A.A. Azad, et al. · European Journal of Cancer · 2

Tumour dosimetry across 6 cycles of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results from the VISION sub-study

2025 · K Herrmann, B J Krause, et al. · Nuklearmedizin - NuclearMedicine

1607P Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)

2024 · L.G. Horvath, H-M. Lin, et al. · Annals of Oncology

Letter to the editor regarding ‘Misclassified confounders in the second interim analysis of the MAGNITUDE trial’ by P. Chen, M. Liu, G.Y. Li, F. Sun, T. Li

2023 · K.N. Chi · Annals of Oncology

512 NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion

2010 · K. Gelmon, S. Dent, et al. · European Journal of Cancer Supplements

Works count: 14

Citation count: 340

H-index: 5

I10-index: 5